PRODUCTS SERVICES COMPANY CONTACT FAQ

Search Dictionary Mobile

Login

Gerd Ritter Selected Research

Antigens

07/2008	Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
12/2007	Expression and purification of the cancer antigen SSX2: a potential cancer vaccine.
02/2007	Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.
08/2006	Directed evolution for improved secretion of cancer-testis antigen NY-ESO-1 from yeast.
01/2006	NY-ESO-1: review of an immunogenic tumor antigen.
01/2006	Generation of monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2.
12/2005	Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
10/2005	Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses.
08/2005	CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients.
11/2004	Real-Time, label-free monitoring of tumor antigen and serum antibody interactions.
11/2004	Identification of the gonad-specific anion transporter SLCO6A1 as a cancer/testis (CT) antigen expressed in human lung cancer.
11/2004	Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer.
07/2004	Glycosylation profiles of the human colorectal cancer A33 antigen naturally expressed in the human colorectal cancer cell line SW1222 and expressed as recombinant protein in different insect cell lines.
03/2004	[Expression of multiple cancer-testis antigen genes in non-small cell lung cancer treated by chemotherapy prior surgery]
09/2003	NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
06/2003	Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients.
08/2002	Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations.

Articles by Research Topic

Disease

14	Neoplasms (Cancer) 07/2008 - 08/2002
8	Testicular Neoplasms (Testicular Cancer) 02/2007 - 04/2002
3	Ovarian Neoplasms (Ovarian Cancer) 08/2008 - 09/2003
3	Colorectal Neoplasms (Colorectal Cancer) 09/2006 - 04/2003
1	Multiple Myeloma 02/2007
1	Fowlpox 09/2006
1	Vaccinia 09/2006
1	Melanoma (Melanoma, Malignant) 12/2005
1	Lung Neoplasms (Lung Cancer) 11/2004
1	Stomach Neoplasms (Stomach Cancer) 11/2004
1	Kidney Neoplasms (Kidney Cancer) 08/2004
1	Small Cell Carcinoma 03/2004
1	Prostatic Neoplasms (Prostate Cancer) 07/2003

Drug/Important Bio-Agent (IBA)

17	AntigensIBA 07/2008 - 08/2002
2	Messenger RNA (mRNA)IBA 07/2003 - 04/2002
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 08/2008
1	CholesterolIBA 01/2007
1	pullulanIBA 01/2007
1	VaccinesIBA 09/2006
1	PerforinIBA 09/2006
1	Monoclonal AntibodiesIBA 01/2006
1	Glycoproteins (Glycoprotein)IBA 01/2006
1	AntibodiesIBA 10/2005
1	B-Lymphocyte Epitopes (B-Cell Epitope)IBA 10/2005
1	HLA-DPB1 (HLA DPB1)IBA 11/2004
1	sibrotuzumabIBA 05/2003
1	Epidermal Growth Factor Receptor (EGF Receptor)IBA 01/2003
1	HLA-A2 Antigen (HLA A2 Antigen)IBA 09/2002

Therapy/Procedure

3	Immunotherapy 01/2006 - 04/2003
1	Stem Cell Transplantation 02/2007
1	Radioimmunotherapy 08/2004
1	Drug Therapy (Chemotherapy) 03/2004
1	Combination Drug Therapy (Combination Chemotherapy) 04/2003